Clinical Trials Logo

Choroidal Melanoma clinical trials

View clinical trials related to Choroidal Melanoma.

Filter by:

NCT ID: NCT06007690 Recruiting - Uveal Melanoma Clinical Trials

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

CoMpass
Start date: December 6, 2023
Phase: Phase 3
Study type: Interventional

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

NCT ID: NCT05266430 Terminated - Choroidal Melanoma Clinical Trials

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

IL
Start date: April 14, 2022
Phase:
Study type: Observational

This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.

NCT ID: NCT04417530 Active, not recruiting - Uveal Melanoma Clinical Trials

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Start date: August 5, 2020
Phase: Phase 2
Study type: Interventional

The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).

NCT ID: NCT03941379 Recruiting - Choroidal Melanoma Clinical Trials

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Start date: March 27, 2019
Phase:
Study type: Observational

The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.

NCT ID: NCT03052127 Completed - Uveal Melanoma Clinical Trials

Study in Subjects With Small Primary Choroidal Melanoma

Start date: February 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

NCT ID: NCT02875652 Completed - Choroidal Melanoma Clinical Trials

Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)

ctDNA MU
Start date: March 21, 2013
Phase: N/A
Study type: Interventional

Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma

NCT ID: NCT01460810 Completed - Choroidal Melanoma Clinical Trials

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

Start date: July 2011
Phase: N/A
Study type: Interventional

A prospective, experimental, case series of 20 patients, with choroidal melanoma, in which pars plana vitrectomy and Silicone oil as vitreous substitute will be used as intraocular shielding for attenuating the deleterious effects of radiation dose delivered to healthy ocular tissue during Iodine-125 plaque brachytherapy treatment and assess if the treatment can reduce the incidence and severity of radiation-induced adverse effects like radiation retinopathy and permanent loss of vision.

NCT ID: NCT01253759 Completed - Choroidal Melanoma Clinical Trials

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

Start date: January 2009
Phase: Phase 4
Study type: Observational

This is a report of 10 years results of combined Transpupillary thermotherapy (TTT) treatment with Indocyanine green (ICG) in controlling small and medium-sized choroidal melanomas.

NCT ID: NCT01251978 Completed - Choroidal Melanoma Clinical Trials

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Start date: July 2010
Phase: Phase 2
Study type: Interventional

Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.

NCT ID: NCT00765921 Completed - Choroidal Melanoma Clinical Trials

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate the safety and tolerability of the anti-VEGF (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton beam irradiation for the treatment of choroidal melanoma by determining the incidence and severity of ocular adverse events. Systemic adverse events will also be evaluated. A secondary objective is to assess the efficacy of ranibizumab in reducing ocular complications that can occur after irradiation.